Celldex Therapeutics Inc. (CLDX)
The price, the headline numbers and the latest news, in one place.
Celldex Therapeutics Inc. (CLDX) Stock Price, Analysis & Data
No data available
| Bid | 34.38 |
| Market Cap | 3.14B |
| Revenue (ttm) | 158K |
| Net Income (ttm) | -300.55M |
| 0.84 | |
| -4.17 | |
| n/a | |
| -9.6 | |
| P/B (ttm) | 4.39 |
| P/S (ttm) | 19851.07 |
| Earnings Date | Nov 9, 2026 |
| Ask | 45.47 |
| Volume | 1,002,530 |
| Avg. Volume (20D) | 1,044,122 |
| Open | 41.40 |
| Previous Close | 41.70 |
| Day's Range | 39.45 - 42.00 |
| 52-Week Range | 21.34 - 45.14 |
| Analyst | Strong Buy |
| Price Target | 56 (40.21%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...
Financial Performance
In 2025, Celldex Therapeutics's revenue was 1.54M, a decrease of -77.99% compared to the previous year's 7.02M. Earnings were -258.76M, an increase of 63.91%.
Financial StatementsAnalyst Forecast
According to 15 analyst ratings, the average rating for CLDX stock is "Strong Buy". The 12-month stock price forecast is 56, which is upside of 40.21% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
